Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.
Filed: 2026-11-16 AccNo: 0001193125-26-462186 Size: 24 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Mizuho Securities analyst Graig Suvannavejh lowered the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $23.00 from $24.00 while maintaining an Outperform rating.
RBC Capital Markets lowered its price target on Corbus Pharmaceuticals Holdings, Inc. to $33 from $36 while maintaining an Outperform rating.
Corbus Pharmaceuticals Holdings, Inc. reported its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical-stage oncology and obesity programs.